Tag: IHL
Impression Healthcare sets out FDA approval strategy for cannabinoid drug candidate IHL-42X
Medical cannabis company Impression Healthcare (ASX: IHL) has revealed it has received an independent strategic assessment report on the FDA approval pathway for cannabinoid IHL-42X...
Impression Healthcare acquires CBD inhalers for distribution under Australia’s Special Access Scheme
Medical cannabis company Impression Healthcare (ASX: IHL) came out of a trading halt late this morning to unveil an initial order for cannabidiol (CBD) pressurised metered-dose...
Impression drafts former AFL star Liam Picken to its advisory board
Australian medical cannabis company Impression Healthcare (ASX: IHL) has taken yet another assertive step towards completing its clinical research program into concussion and traumatic brain...
Impression Healthcare to launch medical cannabis trials for treatment of traumatic brain injury
Australian medical cannabis company Impression Healthcare (ASX: IHL) has finalised the design of a clinical program to assess novel cannabinoid formula IHL-216A on neurocognitive...
Impression Healthcare expands cannabinoid oil sales program
Medical cannabis company Impression Healthcare (ASX: IHL) has expanded its cannabinoid oil sales program that runs side by side with its extensive base of clinical...
Impression Healthcare prepares for obstructive sleep apnoea clinical trial
Medical cannabis company Impression Healthcare (ASX: IHL) is on course to begin a clinical trial using its IHL-42X drug candidate for the treatment of obstructive...
Impression Healthcare files patent for non-intrusive treatment of obstructive sleep apnoea
Medical cannabis company Impression Healthcare (ASX: IHL) is continuing on its path to developing an effective solution for obstructive sleep apnoea (OSA) having filed a...
Impression Healthcare recruits Big Pharma executive to complete cannabinoid drug discovery goal
Medical cannabis company Impression Healthcare (ASX: IHL) has continued its top-tier recruitment drive with the addition of yet another pharmaceutical industry expert into its...
Impression Healthcare files patent application for medicinal CBD drug to alleviate concussion injuries
Impression Healthcare (ASX: IHL) has opted to file a patent application for a neuroprotective agent that could potentially aid people that suffer concussions – a...
Duo of renowned specialists join Impression Healthcare, Incannex CBD oils on route
Following a busy few months on the recruitment and brand licencing fronts, Impression Healthcare (ASX: IHL) has appointed an additional duo of leading medical...
Impression Healthcare appoints two globally renowned medical experts for cannabis medicines projects
Impression Healthcare (ASX: IHL) has bolstered its Medical Advisory Board by appointing two leading medical experts possessing extensive expertise within two key market niches currently being...
Impression Healthcare commences obstructive sleep apnoea clinical trial
Following last week’s deal that saw Impression Healthcare (ASX: IHL) secure the cannabinoid materials it needs to conduct a series of clinical trials, the...
Impression Healthcare secures long term oil supply agreement, unveils new cannabis discovery brand Incannex
Impression Healthcare (ASX: IHL) has moved to extend its medicinal cannabis market coverage after unveiling the all-new cannabinoid drug discovery brand Incannex Pharmaceuticals.
As a...
Impression Healthcare becomes official supplier and research partner to ONE Championship
Barely a week after Aurora announced a deal with the Ultimate Fighting Championship (UFC), Australia’s very own Impression Healthcare (ASX: IHL) has made a...
Impression Healthcare appoints leading medicinal cannabis pioneer Dr Sud Agarwal to its board
Impression Healthcare (ASX: IHL) has tweaked its internal structure by appointing Dr Sud Agarwal, a leading figure in the medicinal cannabis industry as its...
Impression Healthcare extends exclusive deal with FiTGuard for concussion monitoring
Impression Healthcare (ASX: IHL) has extended the global coverage of its Fitguard by Gameday concussion monitoring system by extending its exclusive licencing agreement with...
Impression Healthcare hones in on sleep apnoea trial with proprietary Dronabinol formulation
Impression Healthcare (ASX: IHL) is on the brink of conducting a sleep apnoea trial with its own variant of the cannabinoid medicine Dronabinol after...
Impression Healthcare becomes Boxing Australia’s official supplier and concussion research partner
Impression Healthcare (ASX: IHL) has unveiled a brand-new exclusive research and supply agreement that will see the healthcare company become the official traumatic brain...
Impression Healthcare registers clinical trial for CBD-based mouthwash and toothpaste
Impression Healthcare’s (ASX: IHL) “world first” clinical trial using its cannabidiol (CBD)-based mouthwash and toothpaste to treat gingivitis and periodontitis (gum disease) has now...
Impression Healthcare to supply concussion monitoring FitGuard mouthguard system
Impression Healthcare (ASX: IHL) has inked an exclusive agreement to supply the concussion monitoring FitGuard mouthguard system.
Under the agreement with Force Impact Technologies, Impression...
Impression Healthcare signs first binding agreement with AXIM Biotechnologies, clinical trial imminent
Impression Healthcare (ASX: IHL) is set to deliver a toothpaste and mouthwash product that adds yet another option for consumers searching for cannabidiol-based products.
Earlier...
